Ciprofloxacin Ranbaxy, Filmdragerad tablett 500 mg
Läkemedlet Ciprofloxacin Ranbaxy rekommenderas av 17 personer och rekommenderas inte av 8 personer och har därmed ett genomsnitt på 3 poäng.
Har du använt denna medicin eller läkemedel?
Användarberättelser (Erfarenheter och biverkningar)
Bli den första att dela med av dina erfarenheter
Bildbank för Ciprofloxacin
Ciprofloxacin Accord, Filmdragerad tablett 500 mg , Accord Healthcare AB
Ciprofloxacin Accord, Filmdragerad tablett 750 mg , Accord Healthcare AB
Snabbfakta
Namn:
Ciprofloxacin Ranbaxy Filmdragerad tablett 500 mg
Receptstatus:
Receptbelagt
ATC-kod:
J01MA02
Läkemedelstillverkare:
Ranbaxy
Läkemedelsform och styrka:
Filmdragerad tablett 500 mg
Mer information:
Mer information om Ciprofloxacin Ranbaxy på Läkemedelsverket
På den här sidan kan du som användare av läsa på och dela erfarenheter och biverkningar
Till höger kan du se hur Medicinkollen håller koll på hur riktiga användare rekommenderar läkemedlet, och du kan förstås ge din egen rekommendation samt så kan du läsa blogginlägg och se videoklipp för .
Svenska nyheter och bloggar om (Ciprofloxacin Ranbaxy)
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news
New York Times | Medicines Made in India Set Off Safety Worries New York Times Dr. Hamburg was met by Indian officials and executives who, shocked by recent F.D.A. export bans of generic versions of popular medicines ? like the acne drug Accutane, the pain drug Neurontin and the antibiotic Cipro ? that the F.D.A. determined ... |
In-PharmaTechnologist.com | Ranbaxy to Pay $500 Million in Adulterated Drugs Case Wall Street Journal (India) The generic drugs at issue were manufactured at Ranbaxy's facilities in Paonta Sahib and Dewas, India. They include acne drug Sotret, epilepsy and nerve pain drug gabapentin, and antibiotic ciprofloxacin. Ranbaxy said the financial provision it made in ... Generic Drug Maker Pleads Guilty in Federal Case Ranbaxy Pleads Guilty to Manufacturing Adulterated Drugs Ranbaxy 'systematically violated' good manufacturing practices: whistleblower |
Nature.com | Falsified data gets India's largest generic drug-maker into trouble Nature.com Ranbaxy Laboratories ? India's biggest drug maker and one of the largest generics firms in the world ? has been slapped with tough penalties by the US Food and Drug Administration (FDA) after it was repeatedly caught falsifying data from one of its ... |
Livemint | India sends substandard generic drugs to Africa, say researchers Livemint Washington: Generic drugs that some Indian companies send to African countries are lower quality than the same medicines the companies sell at home and outside Africa, according to tests of 1,470 samples, researchers said. Two widely used antibiotics ... |
FDA approves generic forms of ciprofloxacin CIDRAP Jun 14, 2004 (CIDRAP News) ? The Food and Drug Administration (FDA) last week approved the first generic versions of ciprofloxacin (Cipro), the antibiotic that drew national attention when it was used after the mail-borne anthrax attacks in 2001 ... |
Medscape | FDA Strengthens Neuropathy Warning for Fluoroquinolones Medscape There are 6 FDA-approved fluoroquinolone drugs on the market: ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, and ofloxacin. In 2011, 23 million patients received a prescription for oral fluoroquinolone drugs from outpatient ... |
Top 200 Drugs of 2012 Pharmacy Times 70, Ciprofloxacin HCl, Actavis, 130, Atenolol, Ranbaxy, 190, Amlodipine Besylate, Ascend Labs. 71, Lipitor, Pfizer, 131, Omeprazole (Rx), Apotex, 191, HYCD/APAP, Amneal. 72, Escitalopram Oxalate, Teva, 132, Digoxin, Lannett, 192, Azithromycin, Sandoz. |
Firstpost | Malvinder Singh hits back at Daiichi, insists FDA charges were in public domain Firstpost A day after pharma major Daiichi Sankyo alleged that certain former shareholders of Ranbaxy concealed and misrepresented critical information about the US justice department and the USFDA probe, former Ranbaxy CEO Malvinder Singh denied any ... |
The Hindu | Questions about India's drug industry The Hindu ... of a series of FDA investigations of Ranbaxy facilities in India, particularly of the two that focussed on production for U.S. markets: Paonta Sahib and Dewas, where Ranbaxy manufactured Sotret and two other popular drugs, Gabapentin and Ciprofloxacin. |